• 1. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 2. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 3. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Primary amines

Recent Advances in the Study of 2-(Adamantan-2-yl)ethan-1-amine (CAS: 59807-53-3) in Chemical Biology and Pharmaceutical Research

2-(Adamantan-2-yl)ethan-1-amine (CAS: 59807-53-3) is a structurally unique compound featuring an adamantane moiety, which has garnered significant attention in chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. Recent studies have explored its role as a versatile scaffold for designing novel bioactive molecules, particularly in the context of central nervous system (CNS) disorders, antimicrobial agents, and antiviral therapies. This research brief synthesizes the latest findings on this compound, highlighting its pharmacological properties, synthetic methodologies, and therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry investigated the use of 2-(adamantan-2-yl)ethan-1-amine as a building block for developing dopamine receptor modulators. The researchers demonstrated that derivatives of this compound exhibited high affinity for D2 and D3 receptors, suggesting potential applications in treating Parkinson's disease and schizophrenia. The study employed molecular docking and in vitro binding assays to validate the interactions, with the adamantane moiety contributing to enhanced blood-brain barrier permeability.

In the realm of antimicrobial research, a team from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters that 2-(adamantan-2-yl)ethan-1-amine derivatives displayed potent activity against multidrug-resistant bacterial strains, including MRSA. The rigid adamantane structure was found to improve metabolic stability, while the amine functionality allowed for further derivatization to optimize antibacterial efficacy. These findings open new avenues for addressing antibiotic resistance.

Another groundbreaking application emerged from a 2024 preprint in ChemRxiv, where researchers utilized 2-(adamantan-2-yl)ethan-1-amine as a key intermediate in synthesizing novel SARS-CoV-2 main protease inhibitors. The compound's ability to mimic hydrophobic protein interactions while maintaining synthetic accessibility made it an attractive candidate for antiviral drug design. Preliminary in silico and in vitro data showed promising inhibition kinetics, warranting further preclinical evaluation.

From a synthetic chemistry perspective, recent advancements have focused on developing more efficient routes to produce 2-(adamantan-2-yl)ethan-1-amine. A 2023 paper in Organic Process Research & Development described a scalable, green chemistry approach using catalytic hydrogenation of readily available adamantane precursors, achieving >90% yield with reduced environmental impact compared to traditional methods. This innovation addresses previous challenges in large-scale production for pharmaceutical applications.

The unique physicochemical properties of 2-(adamantan-2-yl)ethan-1-amine, including its lipophilicity (logP ~3.2) and molecular rigidity, continue to inspire novel applications in drug delivery systems. Recent work published in the International Journal of Pharmaceutics demonstrated its incorporation into lipid nanoparticles for targeted delivery of siRNA therapeutics, leveraging the adamantane group's membrane interaction capabilities to enhance cellular uptake efficiency in hard-to-transfect cell types.

As research progresses, safety profiling remains a critical consideration. A 2024 toxicology study in Regulatory Toxicology and Pharmacology provided comprehensive data on the compound's metabolic pathways and potential hepatotoxicity risks at high doses, informing future structure-activity relationship optimizations. These findings underscore the importance of balancing therapeutic potential with safety considerations in derivative development.

In conclusion, 2-(adamantan-2-yl)ethan-1-amine (59807-53-3) represents a multifaceted tool in modern medicinal chemistry, with recent breakthroughs spanning neurological, infectious disease, and drug delivery applications. The convergence of synthetic innovations, biological insights, and computational modeling approaches continues to unlock its full potential, positioning this compound as a valuable asset in addressing unmet medical needs across multiple therapeutic areas.

• 72055-19-7(Bicyclo[2.2.1]heptane-2-ethanamine,(1R,2R,4S)-rel-)
• 4354-60-3(CYCLOHEXANEHEXANAMINE)
• 749799-45-9(4-(propan-2-yl)cyclohexylmethanamine)
• 785018-97-5(3-cyclohexylbutan-1-amine)
• 4442-85-7(2-cyclohexylethan-1-amine)
• 4361-44-8(3-cyclohexylpropan-1-amine)
• 408312-01-6(2-(4-methyl-cyclohexyl)-ethylamine)
• 4441-59-2(4-Cyclohexylbutan-1-amine)
• 102450-00-0(2-(2-Methylcyclohexyl)ethan-1-amine)
• 22643-14-7(Cyclohexanamine, N-octyl-)